Literature DB >> 22022824

Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions.

Lara Magro1, Ugo Moretti, Roberto Leone.   

Abstract

INTRODUCTION: Drug-drug interactions (DDIs) arise in numerous different ways, involving pharmacokinetic or pharmacodynamic mechanisms. Adverse drug reactions are a possible consequence of DDIs and health operators are often unaware of the clinical risks of certain drug combinations. Many papers on drug interactions have been published in recent years, but most of them focused on potential DDIs while few studies have been conducted on actual interactions. AREAS COVERED: This paper reviews the epidemiology of actual DDIs in outpatients as well as in hospital settings and in spontaneous reporting databases. The incidence of actual DDIs is consistently lower than that of potential DDIs. However, the absolute number of patients involved is high, representing a significant proportion of adverse drug reactions. The importance of risk factors such as age, polypharmacy and genetic polymorphisms is also evaluated. The relevance and efficacy of tools for recognizing and preventing DDIs are discussed. EXPERT OPINION: Potential DDIs far outnumber actual drug interactions. The potential for an adverse interaction to occur is often theoretical, and clinically important adverse effects occur only in the presence of specific risk factors. Several studies have shown the efficacy of computers in early detection of DDIs. However, a correct risk-benefit evaluation by the prescribing physician, together with a careful clinical, physiological and biochemical monitoring of patients, is essential. Future directions of drug interaction research include the increasing importance of pharmacogenetics in preventing DDIs and the evaluation of interactions with biological drugs.

Entities:  

Mesh:

Year:  2011        PMID: 22022824     DOI: 10.1517/14740338.2012.631910

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  70 in total

1.  A cross-sectional study on drug use in multiple system atrophy.

Authors:  María Verónica Rey; Santiago Perez-Lloret; Anne Pavy-Le Traon; Wassilios G Meissner; Francois Tison; Olivier Rascol
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

2.  Potential drug interactions in patients with a history of cancer.

Authors:  L Chen; W Y Cheung
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

3.  Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions: a prospective cohort study.

Authors:  Neža Muhič; Ales Mrhar; Miran Brvar
Journal:  Eur J Clin Pharmacol       Date:  2017-03-15       Impact factor: 2.953

4.  Stressors and Resources Related to Medication Management: Associations With Spousal Caregivers' Role Overload.

Authors:  Courtney A Polenick; Sarah D Stanz; Amanda N Leggett; Donovan T Maust; Nancy A Hodgson; Helen C Kales
Journal:  Gerontologist       Date:  2020-01-24

5.  Evaluation of Clinical Relevance of Drug-Drug Interaction Alerts Prior to Implementation.

Authors:  S M M Meslin; W Y Zheng; R O Day; E M Y Tay; M T Baysari
Journal:  Appl Clin Inform       Date:  2018-11-28       Impact factor: 2.342

6.  Drug-drug interaction knowledge to save the patient from iatrogenic disease and to improve the diagnostic process.

Authors:  Enrica Cecchi
Journal:  Intern Emerg Med       Date:  2019-01-04       Impact factor: 3.397

7.  Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury.

Authors:  Charles E Leonard; Colleen M Brensinger; Thanh Phuong Pham Nguyen; John R Horn; Sophie Chung; Warren B Bilker; Sascha Dublin; Samantha E Soprano; Ghadeer K Dawwas; David W Oslin; Douglas J Wiebe; Sean Hennessy
Journal:  Biomed Pharmacother       Date:  2020-07-30       Impact factor: 6.529

8.  Toward a complete dataset of drug-drug interaction information from publicly available sources.

Authors:  Serkan Ayvaz; John Horn; Oktie Hassanzadeh; Qian Zhu; Johann Stan; Nicholas P Tatonetti; Santiago Vilar; Mathias Brochhausen; Matthias Samwald; Majid Rastegar-Mojarad; Michel Dumontier; Richard D Boyce
Journal:  J Biomed Inform       Date:  2015-04-24       Impact factor: 6.317

9.  Drug-drug interactions in patients with acute coronary syndrome across phases of treatment.

Authors:  Ana V Pejčić; Slobodan M Janković; Goran Davidović
Journal:  Intern Emerg Med       Date:  2018-11-27       Impact factor: 3.397

Review 10.  Patient Characteristics Associated with Adverse Drug Events in Hospital: An Overview of Reviews.

Authors:  Silvija Mihajlovic; Jeremie Gauthier; Erika MacDonald
Journal:  Can J Hosp Pharm       Date:  2016-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.